| Document |
Document Title |
|
JP2011057557A |
To provide an oxygen isotope-labeling reagent which facilitates the progression of a reaction on the synthesis of an oxygen isotope-labeled compound, can give many kinds of oxygen isotope-labeled compounds, and is a supply source for the...
|
|
JP2011055842A |
To provide a new method for preparation of optically active intermediates which may be used for the preparation of escitalopram.There is provided a method for isolation and purification of S-enantiomer of the diol represented by formula ...
|
|
JP2011057618A |
To provide a practical process for producing optically active adamantylpropionic acid.The process for producing optically active adamantylpropionic acid comprises a step of reacting 2-(1-adamantyl)propionic acid with an amine selected fr...
|
|
JP4645986B2 |
The present invention provides processes for producing a (4E)-5-chloro-2-isopropyl-4-pentenoate and an optical isomer of the (4E)-5-chloro-2-isopropyl-4-pentenoate, namely a process for producing a (4E)-5-chloro-2-isopropyl-4-pentenoate ...
|
|
JP2011042647A |
To provide a method for the producing optically active nipecotamide by an advantageous process on a commercial scale.The method for producing optically active nipecotamide includes the steps of: reacting nipecotamide with optically activ...
|
|
JP2011032214A |
To provide a method for producing an optically pure 12-hydroxystearic acid having a clear stereochemical absolute configuration, which is conventionally considered difficult, namely a method for producing (S)-12-hydroxystearic acid havin...
|
|
JP2011024572A |
To provide a method for producing an optically active α-amino acids important as a production intermediate for various industrial chemicals, agrochemicals, and pharmaceuticals in high quality and at low cost.In the method, a resolution ...
|
|
JP2011502471A |
The invention relates to a process for preparing an enantiomerically and/or diastereomerically enriched ester or thioester having at least two adjacent chiral centres, wherein a mixture of stereoisomers of a secondary alcohol or thiol ha...
|
|
JP2011016751A |
To provide a method for producing an optically active 3-aminopiperidine-1-carboxylate compound, and to provide an intermediate used for the production method.The method for producing the optically active compound comprises a process for ...
|
|
JP2011503004A |
Embodiments in accordance with the present invention provide for forming essentially pure diastereomers of 5/6-substituted norbornene-type monomers. Further, embodiments in accordance with the present invention encompass polymerizing suc...
|
|
JP2011012032A |
To provide an industrially advantageous production method of an optically active 3-aminopiperidine.3-Aminopiperidine is optically resolved by a diastereomer method using as a resolving agent (A) optically active 2-methoxyphenylacetic aci...
|
|
JP4615861B2 |
Methods for production of chirally pure alpha -amino acids and N-sulfonyl alpha -amino acids are described. An aldehyde and a cyanide salt are reacted with an alpha -methylbenzylamine to afford a product. The product reacts with a strong...
|
|
JP4617066B2 |
Enantiomer enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo(4.3.0)nonane (I) is effected by continuous countercurrent chromatography, preferably using a simulated moving bed (SMB) plant.
|
|
JP4608938B2 |
|
|
JP2011001268A |
To provide a method of producing high purity lactide at a high yield.The method of producing refined high purity lactide includes a process of bringing (a) a lactide mixture comprising L-lactide and/or D-lactide and meso-lactide and (b) ...
|
|
JP4604380B2 |
|
|
JP2010540493A |
The invention relates to a large-scale method for producing salts of (IR,5S) anhydroecgonine esters. The salt formation and selective crystallization of (IR,5S) anhydroecgonine esters with chiral acids is highly efficient in producing an...
|
|
JP4595178B2 |
|
|
JP4594099B2 |
The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1α,25 dihydroxy vitamin D3. These compounds are useful for treating bone dise...
|
|
JP2010536791A |
Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
|
|
JP4591998B2 |
|
|
JP4590038B2 |
The invention relates to a method for the preparation of an enantiomerically pure imidazolyl compound of the general formula wherein: n is 0 or 1; m is 1 or 2; R1 is hydrogen, methyl or ethyl; and C* denotes a chiral centre; as well as i...
|
|
JP2010535177A |
The present invention refers to a process for the resolution into one of its enantiomers of the racemate of compound of formula (I): which comprises separating said one of its enantiomers from a diastereoisomeric salt of formula (II), wh...
|
|
JP4576642B2 |
|
|
JP4573223B2 |
|
|
JP2010241815A |
To provide a new salt of monatin and an organic amine, hopeful as a sweetener, to provide a crystal thereof, and to provide a new method for making a resolution of the monatin's stereoisomers.As the new salt of monatin, a salt of the mon...
|
|
JP2010533681A |
The invention provides a new enantioselective process for the preparation of (S)-pregabalin, or a pharmaceutical acceptable addition acid salt comprising: acid hydrolysis of the dioxolan ring of a chiral compound of general formula (I) t...
|
|
JP4564846B2 |
The invention relates to a method of administering N-(3,5-bis-trifluoromethyl-benzoyl)-2-benzyl-4-(quinoloylami
no)-piperidines of the formula wherein Y is ═N— or ═N(O)—, R is OH when Y is ═N— and R is H when Y is ═N(O)— ...
|
|
JP2010532767A |
An optically active N-(±-mercaptopropionyl)glycine, i.e., R-(-)-N-(±-mercaptopropionyl)glycine or S-(-)-N-(±-mercaptopropionyl)glycine, a preparation method thereof, a pharmaceutical preparation containing the compound or a pharmaceut...
|
|
JP4559856B2 |
N-aryl piperidine substituted biphenylcarboxamides compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment ...
|
|
JP4562229B2 |
|
|
JP4560878B2 |
|
|
JP4555541B2 |
|
|
JP4554076B2 |
The invention relates to a process for preparing (S,S)-8-benzyl-2,8-diazabicyclo[4.3.0]nonane.
|
|
JP4538114B2 |
4-Phenyl-5-hydroxy-1,2,3,6-tetrahydropyridine derivatives (I) are prepared from 4-phenyl-1,2,3,6-tetrahydropyridine (II). The preparation of 4-phenyl-5-hydroxy-1,2,3,6-tetrahydropyridine derivatives of formula comprises: (1) reacting a c...
|
|
JP4534329B2 |
A separating medium containing an optically active poly(N- alpha -methylbenzylmaleimide) represented by the following formula (1): wherein n is a number within a range of from 2 to 10,000, and symbol * represents optically active carbon,...
|
|
JP4533148B2 |
This invention is directed to a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Z, m, n, o, p and r are as defined herein, its preparation, pharmaceutical composition and use as an adenosine A3 receptor ligan...
|
|
JP4532801B2 |
The invention relates to a process for preparing (-)-(1S,4R) N protected 4-amino-2-cylcopentene-1-carboxylate esters represented by the formula (I)wherein R1 and R2 are as described within the specification.
|
|
JP4530172B2 |
There is provided a process for efficiently producing an optically active substance of efonidipine that is useful as an antihypertensive agent or a therapeutic agent for angina pectoris. A process for producing an optically active substa...
|
|
JP4527379B2 |
|
|
JP4524841B2 |
|
|
JP2010527345A |
The present invention provides a novel process for the preparation of a compound of Formula III, and novel processes for preparing escitalopram using the compound of Formula III.
|
|
JP2010527284A |
Among other things, to cause directional motion of chiral objects in a mixture in a chamber, a field is rotated relative to a chamber to cause rotation of the chiral objects. The rotation of the objects causes them to move directionally ...
|
|
JP4521531B2 |
To produce an asymmetric acylation catalyst capable of optically resolving a racemic secondary alcohol with high selectivity in spite of a relatively simple structure. The asymmetric acylation catalyst is used when the racemic secondary ...
|
|
JP4520096B2 |
The present invention provides a method for producing an optically active beta -hydroxy ester compound represented by the general formula: wherein R<1> represents an optionally substituted hydrocarbon group and the like, R<2> represents ...
|
|
JP2010526059A |
According to one aspect of the present invention there is provided a substantially high purity D-(−)-N,N-diethyl-2-(α-naphthoxy)propionamide and a process for the manufacture of substantially higher purity D-(−)-N,N-diethyl-2-(α-na...
|
|
JP4510879B2 |
The present invention particularly relates to a chemoenzymatic process for the stereoselective preparation of both enantiomers of 3-hydroxy-4-trityloxy butanenitrile key intermediates for the preparation of (R)-GABOB by lipase mediated k...
|
|
JP4511723B2 |
The present invention provides various processes for the preparation of (R)-±-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-p
iperidinemethanol. These processes may be characterized by the following scheme:
|
|
JP4511809B2 |
|
|
JP4510447B2 |
This invention relates to novel indane acetic acid derivatives which are useful in the treatment of diseases such as diabetes, obesity, hyperlipidemia, and atherosclerotic diseases. The invention also relates to intermediates useful in p...
|
